Scientific Online Resource System

Heart - Lung (Varna)

Anemia, heart failure and treatment with erythropoiesis-stimulating agents

Mariya Stoyanova Dimova, Elena Stoyanova Marinova, Liliya Stoyanova

Abstract

Anemia is a common concomitant disease in patients with heart failure and is a cause for deteriorating prognosis and poor outcome of the disease. Anemia in the population of patients with heart failure is much more common than in the general population. It is estimated that it varies between 17 and 70% depending on whether the patients are hospitalized or not. The incidence of anemia among the hospitalized for acute heart failure patients in one Bulgarian study is 32.7%. The treatment of this concomitant state is defined by its etiology. The most common causes of anemia in heart failure are iron defficiency, chronic inflamation and chronic kidney disease. The treatment of anemia with erythropoiesis-stimulating agents was initially promising, but the results that came out later showed disappointing data. Erythropoiesis-stimulating agents increase the thrombotic risk, the incidence of stroke, although an increase in the level of hemoglobin is found.


Keywords

anemia, heart failure, recombinant erythropoetin

Full Text


References

Von Haehling S, van Veldhuisen DJ, Roughton M, et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. Eur J Heart Fail 2011;13:656-63.

Ghali JK. Anemia and heart failure. Curr Opin Cardiol 2009;24:172-8.

Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008;52:818–827

Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006;107:1747–50

Grote Beverborg N, Verweij N, Klip IT, et al. Erythropoietin in the general population: reference ranges and clinical, biochemical and genetic correlates. PLoS One 2015;10:e0125215.

Ангелов А., Йотов Й. Клинична характеристика и медикаментозно лечение при болни хоспитализирани с остра сърдечна недостатъчност. Разлики между двата пола. Българска кардиология 2013; 19: 46-50.

Мирчева Л., А. Кишева, А. Ангелов, О. Кунчев, Й. Йотов. Особености в протичането на сърдечната недостатъчност при възрастни пациенти в болнични условия. Списание „Известия на Съюза на учените” – Варна 2012; 17: 25-28.

Ангелов А., Й. Йотов. Чeстотота и рискови фактори за рехоспитализация при болни със сърдечна недостатъчност. Българска Кардиология 2013; 19: 26-31.

Kotecha D, Ngo K, Walters JA, Manzano L, Palazzuoli A, Flather MD. Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials. Am Heart J. 2011;161:822–831

Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P; Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008;117:526–535

Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low ematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590.

Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084

Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;

Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369:381–388.

Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD,Toto R; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032

Desai A, Lewis E, Solomon S, McMurray JJ, Pfeffer M. Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis. Eur J Heart Fail. 2010;12:936–942.

Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, MaggioniAP, McMurray JJ, O’Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ; RED-HF Committees; RED-HF Investigators. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013

Bello N, Lewis E, Desai A, Anand I, Krum I, McMurray J, Olson K, Solomon S, Swedberg K, Veldhuisen D, Young J, Pfeffer M, Increased Risk of Stroke with Darbopoetin Alfa in Anaemic Heart Failure Patients with Diabetes and Chronic Kidney Disease European Journal of Heart Failure (2015)17,1201–1207

Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA; Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363:1146–1155

US Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/.

Kliger AS, Foley RN, Goldfarb DS, Goldstein SL, Johansen K, Singh A,Szczech L. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis. 2013;62:849–859

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 2016; 37 (27): 2129-2200

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–e161.




DOI: http://dx.doi.org/10.14748/hl.v23i0.5870

Refbacks

Font Size


|